Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of “Moderate Buy” by Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has received an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $365.40.

A number of equities analysts recently commented on the company. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research note on Monday, July 13th. TD Cowen lifted their price target on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Finally, Royal Bank Of Canada assumed coverage on shares of Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 price target on the stock.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $346.58 on Monday. The stock has a market cap of $10.26 billion, a PE ratio of 43.43 and a beta of 0.53. Krystal Biotech has a 12-month low of $136.73 and a 12-month high of $382.54. The company has a 50-day moving average of $347.03 and a 200 day moving average of $301.54.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, sell-side analysts forecast that Krystal Biotech will post 7.68 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This represents a 1.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 51,642 shares of company stock worth $16,471,923. Insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Silvant Capital Management LLC purchased a new stake in Krystal Biotech in the second quarter valued at $30,000. Western Wealth Management LLC purchased a new position in shares of Krystal Biotech during the 1st quarter worth $34,000. Greenline Wealth Management LLC purchased a new position in shares of Krystal Biotech during the 4th quarter worth $34,000. Danske Bank A S acquired a new stake in shares of Krystal Biotech during the 3rd quarter worth about $35,000. Finally, UMB Bank n.a. increased its position in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.